Procedures
GvHD
LYMPHOID NEOPLASM, GRAFT VERSUS HOST DISEASE
The histological diagnosis was performed locally and then centrally reviewed by an expert hematopathologist (S.A.P), according to the 2017 edition of the WHO classification of lymphoid neoplasms [The treatment consisted of an induction phase and a consolidation phase with HDT and transplantation, Supplementary Fig. 1.During induction, patients received three courses of Ro-CHOEP, followed by an interim evaluation with CT-scan, BM biopsy (if positive at baseline), and PET (recommended, not mandatory); patients in CR or partial response (PR) received three additional Ro-CHOEP courses. At the end of induction, patients in CR received one DHAP course (cisplatin, cytarabine, dexamethasone) to mobilize peripheral blood stem cells followed by auto-SCT, whereas the patients in PR with a donor available proceeded directly (DHAP not mandatory) to allo-SCT; patients in PR without a donor available, proceeded to DHAP and auto-SCT. Treatment failures at any time during the study, proceeded to salvage treatment, according to each institutional policy.After MTD definition, romidepsin 14 mg/ms was administered by a 4-hours infusion, on days 1 and 8.In patients eligible for auto-SCT, standard conditioning regimens with intravenous BCNU or Fotemustine or CCNU, etoposide, cytarabine, melphalan (BEAM or FEAM or CEAM) were allowed.In patients in PR after induction, allo-SCT was performed if a HLA-identical or one antigen mismatched donor was available. In allo-SCT, a conditioning regimen based on intravenous thiotepa, cyclophosphamide, and fludarabine was recommended, with cyclosporine and short-course methotrexate as graft versus host disease (GvHD) prophylaxis [